S1PR3 Inhibition in alveolar epithelial cells alleviates pulmonary fibrosis by enhancing alveolar barrier function Authors: Mengyao Hao, Guodong Tang, Enjia Zhou, Rong Fu, MingJin Wang, Huimin Jiang, Xiaoguang Chen, Liping Bai, Xiaoxi Lv, Jing Jin Published: 2025 ABSTRACT BackgroundPulmonary fibrosis (PF) is a chronic and progressive respiratory disease characterized by the destruction of the alveolar–capillary barrier. Repeated injury and abnormal repair of alveolar epithelial cells lead to barrier dysfunction and fibroblast activation. The sphingosine-1-phosphate (S1P) and sphingosine-1-phosphate receptor (S1PR) signaling pathways are critical for regulating physiological barrier function. Among the five receptor subtypes, S1PR3 is highly expressed in alveolar epithelial cells, especially after injury, but its specific role in PF remains unclear.MethodsPublic single-cell RNA sequencing datasets were analyzed to examine S1PR3 expression in idiopathic pulmonary fibrosis (IPF) patients. The expression pattern of S1PR3 was validated in bleomycin (BLM)-induced PF mice. To explore its functional role, lung epithelial-specific S1pr3 conditional knockout mice were generated. In vitro, S1PR3 expression was knocked down by siRNA or inhibited by the selective antagonist TY52156 to evaluate its effect on epithelial barrier integrity and tight junction proteins.ResultsS1PR3 expression was markedly upregulated in the epithelial cells of both IPF patients and BLM-induced fibrotic mice. Epithelial-specific deletion of S1pr3 significantly attenuated fibrosis, as evidenced by reduced inflammatory cytokine levels, decreased collagen deposition, and improved alveolar–capillary barrier integrity. Furthermore, pharmacological or genetic inhibition of S1PR3 enhanced the expression of tight junction proteins, including ZO-1, Occludin, and Claudin-4, thereby mitigating epithelial barrier disruption.ConclusionsS1PR3 in alveolar epithelial cells plays a critical role in maintaining alveolar–capillary barrier integrity during pulmonary fibrosis. Targeted inhibition of S1PR3 strengthens tight junctions and alleviates inflammation, suggesting that S1PR3 may serve as a promising therapeutic target for PF.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12931-025-03435-y. Introduction The alveolar‒capillary barrier is a mucosal surface that facilitates the interaction between the alveolar airspace and the parenchyma and serves as a physiological and immune barrier to protect the submucosa from exogenous chemicals [1]. As the most essential place for gas exchange [2], the alveolar‒capillary barrier is composed of epithelial cells, including type I epithelial cells (AT1) and type II epithelial cells (AT2), adjacent pulmonary capillaries and the basement membrane between them. As particularly important components of the alveolar‒capillary barrier, epithelial cells serve different functions under physiological conditions: AT1 cells are primarily responsible for gas exchange, whereas AT2 cells play a critical role in surfactant production and the repair of damaged alveolar tissue [3]. Under pathological conditions, exogenous factors such as pathogens, allergens, and some environmental toxins can damage the integrity of the epithelial barrier, leading to acute inflammatory reactions and secondary lung injury, such as acute lung injury (ALI), acute respiratory disease syndrome (ARDS), and chronic pulmonary fibrosis (PF) [4–6]. Among these respiratory diseases, PF has emerged as a global public health concern in recent years; however, its underlying mechanisms remain incompletely understood, and effective therapeutic strategies are still limited. Dysfunction of the alveolar‒capillary barrier is one of the key mechanisms involved in the development of PF [7]. Repetitive and persistent pulmonary epithelial injury, including aberrant epithelial‒mesenchymal transition (EMT) [8] and the excessive production of profibrotic mediators such as connective tissue growth factor (CTGF) [9] and transforming growth factor-β (TGF-β), is closely associated with the progression of PF. Therefore, strategies to protect the function of alveolar epithelial cells to enhance alveolar‒capillary barrier integrity may offer promising avenues for the prevention and treatment of PF. Sphingosine-1-phosphate (S1P) is a bioactive lipid mediator that binds to five S1P receptors (S1PR1-5), regulating various physiological and pathological processes [10]. Among these receptors, S1PR1 and S1PR3 play crucial roles in the alveolar‒capillary barrier [11–13]. Our previous studies revealed that S1PR1 is highly expressed in capillary endothelial cells and that the inhibition of S1PR1 exacerbates PF whereas S1PR1 modulators prevent PF progression [11]. However, S1PR3 is highly expressed on the lung epithelium [14] and is involved in multiple functions, such as cytoskeletal rearrangement and immune regulation [15, 16]. Previous studies have suggested that S1PR3 couples to Gi and G12/13 and mediates EMT through the enhancement of Smad3 phosphorylation, promoting an epithelial profibrotic response to TGF-β via the Rho/Rho kinase signaling pathway and Rac or through the Gq-mediated activation of phospholipase C (PLC) [17–19], all of which are involved in the process of alveolar barrier injury. By using S1pr3 knockout mice, Murakami et al. found that S1pr3 deficiency alleviates lung inflammation, especially reducing lymphocyte infiltration in the lungs [20]. However, given that S1PR3 is highly expressed in epithelial cells and plays a role in regulating the cytoskeleton, we propose that the anti-inflammatory and antifibrotic effects observed upon S1PR3 inhibition might largely result from the suppression of S1PR3 in alveolar epithelial cells, which in turn improves alveolar‒capillary barrier function. In this study, we found that S1PR3 expression was significantly upregulated in alveolar epithelial cells of IPF patients and in the lung epithelium of a PF mouse model. Epithelial-specific S1pr3 knockout ameliorated PF by reducing the inflammatory response, enhancing epithelial tight junctions, and preserving epithelial barrier integrity. Materials and methods Cell lines To ensure the authenticity and quality of the cell lines, all cells used in this study were tested for mycoplasma contamination before experimentation (Yeasen Biotech, 40612ES25, Shanghai, China), following the manufacturer’s protocol. No mycoplasma contamination was detected in any of the cell lines. Type II epithelial cells were isolated as described previously [11]. In brief, negative magnetic bead selection was applied to isolate mouse lung type II epithelial cells. After single-cell suspensions were obtained from lung tissue, the cells were incubated with 3 µL of anti-mouse antibodies against CD16/32 (101303), CD45 (103104), CD31 (102503), CD104 (123603), and TER-119 (116204) (BioLegend; San Diego, United States). Following incubation, the samples were placed on a magnetic rack for one minute, and the supernatant, which contained type II epithelial cells, was collected. Human pulmonary carcinoma cells (A549) were purchased from the Basic Research Institute of Peking Union Medical College (Beijing, China). A549 cells were cultured in RPMI 1640 (Cat. C11875500BT; Gibco; Grand Island, NY, USA) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin‒streptomycin. The cells were maintained in 100-mm culture dishes (70704001; Wuxi NEST Biotechnology Co., Ltd.; Wuxi, China) in a 37 °C incubator with a 5% CO₂ atmosphere. TY52156 was obtained from MedChemExpress (HY-19736; Monmouth Junction, NJ, USA). Animals Conditional S1pr3 knockout (S1pr3-cKO) mice and Sftpc-CreERT2 (Cre) mice were generated by Cyagen Biosciences (Suzhou, China). Ethics approval was obtained from the Animal Care and Use Committee of the Institute of Materia Medica, Chinese Academy of Medical Sciences, and Peking Union Medical College (Beijing, China). To create offspring with the targeted conditional deletion of S1pr3, fertilized mouse zygotes were injected with S1pr3-targeting gRNA, a donor vector containing loxP sites, and Cas9 mRNA. The resulting S1pr3f/+ mice were then crossed with tissue-specific Sftpc-CreERT2 mice to generate heterozygous pulmonary epithelial-specific S1pr3 knockout mice. S1pr3f/+-Sftpc-CreERT2 mice were subsequently interbred to obtain S1pr3f/f-Sftpc-CreERT2 mice. To induce Cre recombinase activation for the selective deletion of S1pr3 in pulmonary epithelial cells, tamoxifen (40 mg/kg/day, intraperitoneally, Cat.T5648; Sigma Millipore; Burlington, MA, USA) was administered for 6 consecutive days, resulting in the generation of S1pr3-cKO mice. Transgenic mice genotyping S1pr3f/f mice and epithelial cell–specific conditional knockout (S1pr3-cKO) mice were genotyped by PCR. The primer sequences used for genotyping are listed in Supplemental Table S1. PCR was performed under the following conditions: initial denaturation at 95 °C for 3 min, followed by 35 cycles of 95 °C for 30 s (denaturation), 58 °C for 30 s (annealing), and 72 °C for 45 s (extension), with a final extension at 72 °C for 5 min. PCR products were analyzed by agarose gel electrophoresis to confirm the genotypes of the mice. Mouse model of lung fibrosis The bleomycin (BLM)-induced lung fibrosis model was established as previously described [11]. S1pr3-cKO and Cre control mice (6‒8 weeks) were administered bleomycin (50 µL; 2 mg/kg; Nippon Kayaku Co., Ltd.; Tokyo, Japan) via intratracheal instillation, and control mice received 50 µL of sterilized 0.9% saline. Body weight and survival rate were monitored throughout the experiment. After four weeks, the mice were euthanized with pentobarbital sodium (50 mg/kg) for subsequent analyses. RNA extraction and RT‒qPCR Total RNA from pulmonary tissue was extracted using an RNA-quick purification kit (RN001; Shanghai YISHAN Biotechnology Co., Ltd.; Shanghai, China). cDNA was synthesized from the extracted RNA using PerfectStart Green qPCR Super Mix (AQ601-04; TransGen Biotech; Beijing, China). Quantitative PCR (qPCR) was performed on an ABI PRISM 7900 Sequence Detection System (PerkinElmer) following the manufacturer’s instructions. The primer sequences are listed in Supplementary Table 1. RNA-seq The procedures for RNA-seq were described previously [11]. RNA-seq was performed by OE Biotech Co., Ltd. (Shanghai, China). Primary epithelial cells were isolated from S1pr3-cKO mice and Cre mice in Sect. 2.2. Notably, each RNA-seq sample was pooled from two mice due to the limited yield of type II epithelial cells following negative selection. After RNA isolation and library construction, fragments per kilobase of transcript per million mapped reads (FPKM) were calculated. Differential gene expression analysis and functional enrichment analysis were performed using gene set enrichment analysis (GSEA) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. The raw RNA-seq data from GSE193876, GSE190821, GSE199152, GSE246654, and GSE150910 were obtained from the Gene Expression Omnibus (GEO) database (http://www.ncbi.nlm.nih.gov/geo) for subsequent analyses. scRNA-seq The raw data of GSE190889 were obtained from the Gene Expression Omnibus (GEO) database (http://www.ncbi.nlm.nih.gov/geo); this dataset contains single-cell RNA-seq data from the lung tissues of IPF patients and healthy individuals. Epcam+ lung epithelial cells were identified on the basis of an expression matrix and metadata and subsequently grouped into IPF and healthy cohorts. To compare S1PR3 expression between the IPF and healthy cohorts, only epithelial cells with S1PR3 expression > 0 were included in the gene expression analysis with the assistance of Shanghai OE Biotech Co., Ltd. Immunofluorescence staining Prior to tissue collection, mice were euthanized via intraperitoneal injection of sodium pentobarbital at a dose of 100 mg/kg (0.2 mL per 20 g body weight), in accordance with institutional animal care guidelines. Lung tissues were obtained from mice in the Cre-con, S1pr3-cKO-con, Cre-BLM, and S1pr3-cKO-BLM groups. Paraffin-embedded sections were dewaxed sequentially with xylene and graded ethanol. The sections were then incubated overnight at 4 °C with an anti-S1PR3 antibody (CSB-PA007902, 1:500; Cusabio, Houston, TX, USA). After three washes with PBS (5 min each), the sections were incubated with HRP-conjugated goat anti-rabbit IgG (GB23303; Servicebio, Wuhan, China) for 50 min at room temperature in the dark, followed by three washes with PBS with each wash lasting 5 minutes. Subsequently, TSA reagent was added, and the sections were incubated for 10 min at room temperature, protected from light, and then washed three times with TBST. The sections were subsequently incubated overnight at 4 °C with an anti-SFTPC antibody (10774-1-AP, 1:200; Proteintech; Wuhan, China). After three washes with PBS (5 min each), the sections were incubated with Cy3-conjugated goat anti-rabbit IgG (H + L) for 50 min at room temperature in the dark, followed by another three washes with PBS with each wash lasting 5 minutes. For the other immunofluorescence analysis shown in Fig. 5–7, an anti-Occludin (GB111401, 1:800; Servicebio) and E-cadherin (24E10; 1:800; Cell Signaling Technology) were used as the primary antibody; the staining procedure was similar to that used for the anti-SFTPC antibody. Finally, the sections were counterstained with 4’,6-diamidino-2-phenylindole (DAPI; G1012; Servicebio) for 10 min at room temperature in the dark, washed three times with PBS (5 min each) and treated with an autofluorescence quencher (G1401; Servicebio). DAPI-stained nuclei appeared blue under ultraviolet (UV) excitation, and positive signals were visualized using the LV2000 system (Beijing Changheng Rongchuang Technology Co., Ltd.). F-actin staining Cells grown on glass coverslips were fixed with 4% paraformaldehyde for 15 min at room temperature. After washing with PBS, the cells were permeabilized with 0.1% Triton X-100 for 10 min and blocked with 1% BSA for 30 min. The filamentous actin was then labeled by incubating the cells with TRITC-conjugated phalloidin (40734ES75; 100µM; Yeason; Shanghai, China) for 60 min in the dark. Following washes with PBS, the cell nuclei were counterstained with DAPI. Finally, the coverslips were mounted with an anti-fade mounting medium and observed under confocal fluorescence microscope. Pulmonary function The procedures used were previously described [11]. Random mice from each group (n = 7–11 per group) were anesthetized with pentobarbital sodium (50 mg/kg). Lung function was assessed using the flexiVent™ system (Scireq, Montreal, Canada). Four key parameters, namely, total compliance of the respiratory system (Crs), dynamic elastance of the respiratory system (Ers), total resistance of the respiratory system (Rrs), and inspiratory capacity (IC), were assessed. Histological analysis Referencing prior studies, we performed histological analysis for lung tissues [11]. Briefly, lung tissues fixed in 4% paraformaldehyde were placed in embedding boxes. Sections were then subjected to H&E and Masson staining. The Ashcroft score was used as the pathological scoring criterion for H&E staining as previously described [21]. Masson staining was evaluated by calculating the collagen volume fraction (CVF) using the following equation: CVF = (area of blue collagen/total tissue area) × 100%. Hydroxyproline assay The hydroxyproline content in lung tissues was measured using a Hydroxyproline Assay Kit (A030-2-1; Nanjing Jiancheng Bioengineering Institute; Nanjing, China) following the manufacturer’s instructions. Briefly, 20–80 mg of lung tissue (n = 3) was weighed and placed into a test tube, followed by the addition of 1 mL of alkaline hydrolysis solution. The samples were then hydrolyzed in a covered water bath at 95 °C for 20 min. After hydrolysis, the supernatant was collected, and the absorbance was measured at 550 nm using a microplate reader (CLARIOstar Plus, BMGLABTECH, Germany). Western blot analysis Lung tissues from mice were lysed in RIPA buffer (P0013B; Beyotime Institute of Biotechnology, Shanghai, China) containing a protease inhibitor cocktail (P1260; Solarbio LIFE SCIENCES, Beijing, China) on ice for 30 min. The lysates were subsequently centrifuged at 14,000 rpm for 15 min at 4 °C, after which the supernatants were collected. Total protein concentrations were measured using a BCA protein assay kit (B5001; LABLEAD BIOTECH Co., Ltd.; Beijing, China). Equal amounts of protein samples were subjected to sodium dodecyl sulfate‒polyacrylamide gel electrophoresis (SDS‒PAGE) and transferred onto polyvinylidene fluoride (PVDF) membranes. The membranes were blocked with 5% skim milk for 1 h at room temperature, followed by an overnight incubation at 4 °C with the following primary antibodies: anti-S1PR3 (55204-1-AP, 1:1000; Proteintech; Wuhan, China), anti-Occludin (66378-1-Ig, 1:1000; Proteintech), anti-Claudin-4 (s16195-1-AP, 1:100; Thermo Fisher; Waltham, MA, USA), anti-ZO-1 (21773-1-AP; 1:1000, Proteintech), anti-E-Cadherin (20874-1-AP, 1:1000; Proteintech), anti-N-Cadherin (22018-1-AP, 1:1000; Proteintech), anti-Snail (3879, 1:500; Cell Signaling Technology, Inc.; Danvers, MA, USA), anti-Slug (9585, 1:500; Cell Signaling Technology), and anti-β-Actin (TA-09; ZSGB-BIO; Beijing, China). After the membranes were washed three times with TBST for 10 min each, they were incubated with goat anti-rabbit IgG (ZB-2301, 1:2000; ZSGB-BIO) or goat anti-mouse IgG (ZB-2305, 1:2000; ZSGB-BIO) for 1 h at room temperature. After three additional washes with TBST three times, 10 min each., the protein bands were visualized using a chemiluminescence imaging system (5200 series; Tanon Science; Irvine, CA, USA). Band intensities were quantified via densitometric analysis using ImageJ software (National Institutes of Health, Bethesda, MD, USA). SiRNA transfection siRNAs targeting S1PR3 were purchased from KeyGEN BioTECH (Jiangsu Province, China). A total of 1.5 µL (2 µg) of siRNA-S1PR3 was diluted in 200 µL of jetPRIME® buffer (101000027, Polyplus-transfection®, Illkirch-Graffenstaden, France)and vortexed for 10 s. Then, 4 µL of jet PRIME® transfection reagent was added to the mixture, followed by brief vortexing for 1 s and incubation at room temperature for 10 min. The transfection mixture was then added to A549 cells cultured in growth medium and incubated at 37 °C for 48 h. S1PR3 Gene expression levels were subsequently evaluated by PCR. The siRNA sequences are listed in Supplementary Table 2. Transendothelial Electrical Resistance (TEER) A549 cells (2 × 104) were seeded into 24-well Transwell inserts (14341; LABSELECT; Norwich, Ontario, N0J 1P0, Canada). Once the cells reached a confluence of 70–90%, the culture medium was replaced with BEGM Bulletkit epithelial cell medium (CC3710; Lonza; Basel, Switzerland). The cells were then cultured for 7 days at 37 °C in a humidified incubator with 5% CO₂, and the medium was changed daily. After this differentiation period, lipopolysaccharide (LPS, 5 µg/mL) for 8 h was added to A549 cells, which were subsequently stimulated with TY52156 (10 µM, HY-19736, MCE) for 24 h. Electrical resistance (Ω) was measured using a Millicell™ ERS-2 Voltammeter (MERS00002; Millipore; Bedford, MA, USA). Statistical analysis All experimental data were analyzed using GraphPad Prism 8.0 software. Comparisons among/between groups were performed using one-way analysis of variance (ANOVA) or Student’s two-tailed t test, as appropriate. A p value < 0.05 was considered statistically significant. Results S1PR3 is expressed in alveolar epithelial cells and significantly increases after lung injury First, the expression of S1PR3 in the lungs of idiopathic pulmonary fibrosis (IPF) patients was analyzed through single-cell RNA sequencing. The GEO dataset GSE190889 (Homo sapiens) of lung epithelial cells revealed that S1PR3 expression was significantly higher in IPF patients than in healthy individuals (Fig. 1A). Additionally, in human cell lines, S1PR3 expression was higher in primary lung alveolar type II (AT2) cells than in endothelial cells (HUVECs) and lung adenocarcinoma epithelial cells (A549 cells) (Fig. S1A). Moreover, as shown in Fig. S1B, bioinformatics analysis of the GSE199152 dataset (Homo sapiens) indicated the moderate upregulation of S1PR3 expression in inflamed lung tissues, suggesting a potential association between S1PR3 and the progression of lung injury. Through immunofluorescence costaining of S1PR3 and the alveolar type II (AT2) epithelial cell marker SFTPC, we found that in lung tissue, S1PR3 colocalized with SFTPC+ cells, suggesting that S1PR3 is expressed in AT2 cells (Fig. 1B). In addition, S1PR3 expression in epithelial cells significantly increased following bleomycin (BLM) treatment (Fig. 1B), with an MFI higher than that for the non-PF group (Fig. 1C). These results indicate that S1PR3 might be closely related to the pathogenesis of PF. To corroborate these findings, we conducted a bioinformatics analysis of RNA-seq data from the GEO datasets GSE190821 (Mus musculus) and GSE193876 (Mus musculus), and the results revealed that S1pr3 expression was increased in BLM-challenged lung epithelial cells and in mice with LPS-induced lung injury (Fig. 1D-E). In addition, analyses of the GSE246654 (Mus musculus) and GSE150910 (Homo sapiens) datasets indicated that the expression of tight junction proteins such as Tjp1 and Ocln was significantly downregulated in both BLM-challenged mice and IPF patients (Fig. 1F). These results suggest that the elevated expression of S1PR3 in PF may be associated with epithelial barrier disruption. Fig. 1S1PR3 expresses in epithelial cells and significantly upregulates after lung injury. (A) The mRNA expression of S1PR3 in Epcam+cells of IPF patients and healthy donors (right)(n=3) and cell type clustering display (left).(B) Representative images of immunofluorescence analysis of the SFTPC and S1PR3 in lung tissues of PF mice (n=4) and control group (n=4), scale bar: 20 μm.(C) MFI of S1PR3 immunofluorescence in lung tissues of PF mice (n=4) and control group (n=4). Bars represent mean ± SEM, ∗P< 0.05, ∗∗P < 0.01,∗∗∗P< 0.001.(D) The mRNA expression of S1pr3 in epithelial cells and lung tissues between nonfibrotic mice (n=6) and BLM-challenged group (n=9).(E)The mRNA expression of S1pr3 in mice ALI between healthy individuals and LPS-induced lung injury group (n = 4).(F)The mRNA expression of Tjp1, Ocln, Cdh2 in mice between control and BLM-induced lung fibrosis group (left) (n = 3) and TJP1, OCLN in lung tissues between healthy individuals and IPF patients (right) (n = 10) S1PR3 expresses in epithelial cells and significantly upregulates after lung injury. (A) The mRNA expression of S1PR3 in Epcam+cells of IPF patients and healthy donors (right)(n=3) and cell type clustering display (left).(B) Representative images of immunofluorescence analysis of the SFTPC and S1PR3 in lung tissues of PF mice (n=4) and control group (n=4), scale bar: 20 μm.(C) MFI of S1PR3 immunofluorescence in lung tissues of PF mice (n=4) and control group (n=4). Bars represent mean ± SEM, ∗P< 0.05, ∗∗P < 0.01,∗∗∗P< 0.001.(D) The mRNA expression of S1pr3 in epithelial cells and lung tissues between nonfibrotic mice (n=6) and BLM-challenged group (n=9).(E)The mRNA expression of S1pr3 in mice ALI between healthy individuals and LPS-induced lung injury group (n = 4).(F)The mRNA expression of Tjp1, Ocln, Cdh2 in mice between control and BLM-induced lung fibrosis group (left) (n = 3) and TJP1, OCLN in lung tissues between healthy individuals and IPF patients (right) (n = 10) Alveolar type II-specific knockout of S1PR3 mitigates the phenotype of bleomycin-induced pulmonary fibrosis To further investigate the role of epithelial S1PR3 in the pathogenesis of PF, transgenic mice with pulmonary epithelium-specific S1pr3 knockout (S1pr3-cKO) were generated. As described in Fig. 2, heterozygous S1pr3f/+ mice were first generated using CRISPR/Cas9, with guide RNAs (gRNAs) targeting S1pr3 and a loxP-carrying vector introduced into mouse zygotes via electroporation. After validating gRNA efficiency and confirming loxP integration, modified zygotes were transferred into surrogate females to produce heterozygous S1pr3f/+ mice. These mice were subsequently crossed with Sftpc-CreERT2 (Cre) mice, which drove Cre expression in AT2 cells. The offspring (S1pr3f/+-Sftpc-CreERT2) were further intercrossed to obtain homozygous S1pr3f/f-Sftpc-CreERT2 mice. Genotyping results of the transgenic mice were shown in the Supplementary Materials (Fig. S2). To induce S1pr3 deletion in pulmonary epithelial cells, tamoxifen (40 mg/kg/day, i.p.) was administered for 6 days, thereby generating S1pr3-cKO mice, with a knockout efficiency of approximately 76%, as confirmed by Western blot analysis. Then, S1pr3-cKO mice were randomly grouped, and bleomycin (BLM, 50 µL/20 g; 2 mg/kg) was administered via tracheal instillation to induce PF in both S1pr3-cKO and Cre mice. As shown in Fig. 3A-B, S1pr3 knockout alone did not significantly affect the survival rate of the animals (p < 0.05). However, under bleomycin stimulation, the 30-day survival rate of the Cre group decreased to 60%, whereas no death occurred in the S1pr3-cKO-BLM group, accompanied by a significant increase in body weight. We subsequently evaluated pulmonary function in each group of mice. As shown in Fig. 3C, BLM treatment reduced the compliance of the respiratory system (Crs) 50% and inspiratory capacity (IC) 30% in mice and both the elastic respiratory system (Ers) and respiratory resistance (Rrs) were approximately doubled. However, the suppression of S1pr3 in the pulmonary epithelium significantly reversed the BLM-induced reduction in Crs, as did the increases in Ers and Rrs, indicating that S1pr3 deletion ameliorated BLM-induced lung dysfunction. H&E staining further revealed that BLM severely disrupted the lung architecture and induced inflammatory cell infiltration in Cre-BLM mice, whereas S1pr3-cKO-BLM mice exhibited dramatically preserved lung structure and reduced inflammation (Fig. 3D-E). Similarly, Masson staining revealed marked collagen deposition in the lungs of Cre-BLM mice, whereas S1pr3-cKO-BLM mice exhibited attenuated fibrosis to some degree, with no apparent changes under basal conditions (Fig. 3F-G). Hydroxyproline is a nonessential amino acid unique to collagen, and its content could also reflect the severity of PF [22]. Consistent with the above findings, we found that the level of hydroxyproline in S1pr3-cKO-BLM mice was lower than that in Cre-BLM mice to some extent (Fig. S3), confirming that epithelial S1pr3 deletion alleviates BLM-induced PF in mice. Fig. 2S1pr3 lung epithelial-specific knockout transgenic mice has been constructed by CRISPR/Cas9 S1pr3 lung epithelial-specific knockout transgenic mice has been constructed by CRISPR/Cas9 Heterozygous S1pr3f/+ mice were first generated by CRISPR/Cas9 technology and subsequently crossed with Sftpc-CreERT2 mice to obtain heterozygous pulmonary epithelial S1pr3 knockout mice, S1pr3f/+-Sftpc-CreERT2. These were then intercrossed to produce homozygous S1pr3f/f-Sftpc-CreERT2 mice (S1pr3-cKO). To confirm the knockout efficiency, lung epithelial cells were isolated from Cre control mice and S1pr3-cKO mice, and S1PR3 protein expression was analyzed by Western blot. Fig. 3S1pr3 knockout could alleviate bleomycin-induced lung fibrosis.(A)Survival curve of S1pr3 deficiency on BLM-induced mouse lung fibrosis model, Cre-con group vs. S1pr3-cKO-con group (left), and Cre-BLM group vs. S1pr3-cKO-BLM group (right)(n = 8–13).(B) Body weight of four groups during the study (n = 8–13). (C) Detection of lung function, involving Crs, Rrs Ers and IC (n = 7–11). (D) Representative images of H&E staining, scale bar, 1000 μm, 200 μm. (E) Ashcroft score of lung inflammatory cells infiltration by H&E staining. (n = 4). (F) Histological analysis of collagen deposition by Masson staining, scale bar, 1000 μm, 200 μm. (G) Quantified collagen volume fraction by Masson staining (n = 4) S1pr3 knockout could alleviate bleomycin-induced lung fibrosis.(A)Survival curve of S1pr3 deficiency on BLM-induced mouse lung fibrosis model, Cre-con group vs. S1pr3-cKO-con group (left), and Cre-BLM group vs. S1pr3-cKO-BLM group (right)(n = 8–13).(B) Body weight of four groups during the study (n = 8–13). (C) Detection of lung function, involving Crs, Rrs Ers and IC (n = 7–11). (D) Representative images of H&E staining, scale bar, 1000 μm, 200 μm. (E) Ashcroft score of lung inflammatory cells infiltration by H&E staining. (n = 4). (F) Histological analysis of collagen deposition by Masson staining, scale bar, 1000 μm, 200 μm. (G) Quantified collagen volume fraction by Masson staining (n = 4) Knocking down epithelial S1pr3 enhances the ECM‒receptor interaction in AT2 cells and concurrently attenuates inflammatory responses AT2 cells were isolated from transgenic mice using negative magnetic bead sorting (CD16/32, CD45, CD31, CD104, and TER119), followed by RNA-seq to investigate gene expression changes and pathway enrichment after S1pr3 knockout. Each sample consisted of pooled primary epithelial cells from two mice due to the limited yield of AT2 cells after negative sorting (Fig. 4A). As demonstrated in Fig. 4B and S4A, a substantial number of genes presented altered expression following S1pr3 deletion, with 1033 genes upregulated and 1285 downregulated between the S1pr3-cKO-con group and the Cre-con group. KEGG pathway enrichment analysis revealed that the genes that were differentially expressed between the Cre-con and S1pr3-cKO-con groups were enriched predominantly in pathways related to cytokine‒cytokine receptor interactions, chemokine signaling, ECM‒receptor interactions and focal adhesion (Fig. 4C). GSEA confirmed that the deletion of S1pr3 affected both the inflammatory response and intercellular adherens junctions (Fig. 4D). Similarly, GO enrichment analysis revealed that the differentially expressed genes were enriched primarily in cellular components associated with the ECM and cell junctions, as well as in the biological process of biological adhesion (Fig. S4B). In the S1pr3-cKO-BLM group, 730 genes were upregulated, and 659 genes were downregulated (Fig. 4E, S4C). KEGG analysis revealed that the differentially expressed genes in the S1pr3-BLM group were significantly enriched in ECM‒receptor interaction pathways (Fig. 4F). Moreover, GO analysis demonstrated enrichment in critical biological processes such as biological adhesion and essential cellular components (Fig. S4D). In particular, compared with the Cre-BLM group, in the S1pr3-cKO-BLM group, pathways related to cell adhesion, focal adhesion and fibroblast growth factor receptor binding were significantly enriched (Fig. 4G). Thus, these results suggest that the protective effect of S1pr3 knockout might be closely associated with an increase in epithelial intercellular junctions. Fig. 4Bioinformatics analysis shows the effects of S1pr3 knockout on fibrosis-associated gene expression. (A) Negative magnetic bead sorting (CD16/32, CD45, CD31, CD104, TER119 antibodies) was used to isolate AT2 cells from transgenic mice lung suspension for RNA-seq analysis. (B) Heatmap of differentially expressed genes mRNA expression of AT2 of the lung between Cre-con and S1pr3-cKO-con (n = 2). (C) KEGG enrichment analysis of differentially expressed genes between S1pr3-cKO -con and Cre-con (n = 2). (D) GSEA of Cre-con and S1pr3-cKO-con was performed (n = 2). (E) Heatmap of differentially expressed genes mRNA expression of AT2 of the lung between Cre-BLM and S1pr3-cKO-BLM (n = 2). (F) KEGG enrichment analysis of differentially expressed genes between S1pr3-cKO-BLM and Cre-BLM (n = 2). (G) GSEA of S1pr3-cKO-BLM and Cre-BLM was performed (n = 2) Bioinformatics analysis shows the effects of S1pr3 knockout on fibrosis-associated gene expression. (A) Negative magnetic bead sorting (CD16/32, CD45, CD31, CD104, TER119 antibodies) was used to isolate AT2 cells from transgenic mice lung suspension for RNA-seq analysis. (B) Heatmap of differentially expressed genes mRNA expression of AT2 of the lung between Cre-con and S1pr3-cKO-con (n = 2). (C) KEGG enrichment analysis of differentially expressed genes between S1pr3-cKO -con and Cre-con (n = 2). (D) GSEA of Cre-con and S1pr3-cKO-con was performed (n = 2). (E) Heatmap of differentially expressed genes mRNA expression of AT2 of the lung between Cre-BLM and S1pr3-cKO-BLM (n = 2). (F) KEGG enrichment analysis of differentially expressed genes between S1pr3-cKO-BLM and Cre-BLM (n = 2). (G) GSEA of S1pr3-cKO-BLM and Cre-BLM was performed (n = 2) S1pr3 knockout in lung epithelial cells enhances the expression of cell junction proteins and increases lung barrier function On the basis of the phenotypic and bioinformatics analysis results above, we further investigated the mechanism by which S1pr3-cKO enhances epithelial barrier integrity following BLM treatment. In Fig. 5A, the heatmap shows a significant reduction in the expression of inflammation-related genes in the S1pr3-cKO-con group; in particular, the expression of chemokines and chemokine receptors, such as C-C motif chemokine ligand 3 (CCL3) and C-X-C motif chemokine ligand 5 (CXCL5), was markedly reduced. This finding is consistent with the KEGG analysis results, suggesting that S1pr3 knockout could suppress the inflammatory response. Additionally, as shown in Fig. 5B (left), heatmaps revealed a moderate increase in adherens junction-related genes, such as cadherin 5 (cdh9), and tight junction-related genes, such as claudin 5 (Cldn5), in the S1pr3-cKO-con group compared with that observed in the Cre-con group (Fig. 5B-right). Consistently, the qPCR results indicated a significant increase in Ocln expression upon S1pr3 knockout, with expression levels approximately threefold higher compared to the Cre-con group (Fig. S5A). As shown in Fig. 5C, we also observed that ECM-related gene expression was reduced in the S1pr3-cKO-con group, indicating a potential role of S1PR3 in regulating ECM remodeling. Compared with those in the Cre-con group, the expression of genes related to ECM deposition, such as fibronectin 1 (Fn1) and Snail family transcriptional repressor 1 (Snai1), was markedly reduced by approximately 50% (Fig. 5C). These findings indicate that S1pr3 knockout facilitates cell junction formation while inhibiting ECM deposition. Upon BLM challenge, the expression of genes related to collagen synthesis, such as collagen type VI alpha 3 chain (Col6a3) and collagen type XIII alpha 1 chain (Col13a1), was lower in the S1pr3-cKO-BLM group than in the Cre-BLM group (Fig. 5D); moreover, the expression of genes involved in tight junctions was significantly lower, whereas the expression of genes related to ECM deposition was markedly higher (Fig. S5B-E). As shown in Fig. 5E, the expression of the representative mesenchymal markers Acta2, Fn1, and Cdh2 was downregulated whereas the expression of Cdh1 was considerably upregulated in the S1pr3-cKO-BLM group. These results indicate that the knockout of S1pr3 effectively enhances the expression of cell junction proteins while reducing collagen synthesis and excessive ECM deposition, which is beneficial for counteracting the formation of PF [23]. Western blot analyses of lung tissue samples from mice confirmed that S1pr3 deletion in AT2 cells increased the expression of tight junction-related proteins, such as Zonula occludens-1 (ZO-1) and Occludin, and the expression of adhesion junction-related proteins, such as E-cadherin, and decreased the expression of N-cadherin and Snail (Fig. 5F). Moreover, after challenge with BLM, the expression of tight junction-related proteins, such as Occludin, ZO-1, and Claudin-4, was substantially 50% higher and that of Snail and Slug were 50% lower in the S1pr3-cKO-BLM group than in the Cre-BLM group (Fig. 5G). Immunofluorescence staining further revealed that S1pr3 knockout in AT2 cells increased the expression of Occludin (Fig. 5H). These results indicate that the deletion of S1pr3 in AT2 cells promotes cell junction protein expression and improves epithelial barrier integrity, which may contribute to the attenuation of PF. Fig. 5S1pr3 knockout in lung epithelial cells could enhance the expression of tight junction proteins and increase the lung barrier function. (A) Heatmap analysis of inflammation related genes (left) and the FPKM of Ccl3 and Cxcl5 (right) in Cre-con and S1pr3-cKO-con groups (n = 2). (B) Heatmap analysis of cell junction related genes (left) and the FPKM of Cdh9 and Cldn5 (right) in Cre-con and S1pr3-cKO-con groups (n = 2). (C) Heatmap analysis of ECM related genes (top) and the FPKM of Fn1 and Snai1 (bottom) in Cre-con and S1pr3-cKO-con groups (n = 2). (D) Heatmap analysis of collagen synthesis related genes (top) and the FPKM of Col6a1 and Col13a1 (bottom) in Cre-BLM and S1pr3-cKO-BLM groups (n = 2). (E) The mRNA expression of Cdh2, Acta2, Fn1 and Cdh1 in Cre-BLM and S1pr3-cKO-BLM groups by RT-qPCR (n = 3). (F) Western blot and quantitative statistics of ZO-1, E-Cadherin, N-Cadherin, Occludin, Snail and β-Actin in the lung tissues of Cre-con and S1pr3-cKO-con groups (n = 4). (G) Western blot and quantitative statistics of ZO-1, Occludin, Claudin-4, Snail, Slug and β-Actin in the lung tissues of Cre-BLM and S1pr3-cKO-BLM groups (n = 4). (H) Representative images of IF staining and MFI of Occludin immunofluorescence in the lung tissues of Cre-BLM and S1pr3-cKO-BLM groups. Bars represent mean ± SEM, ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 S1pr3 knockout in lung epithelial cells could enhance the expression of tight junction proteins and increase the lung barrier function. (A) Heatmap analysis of inflammation related genes (left) and the FPKM of Ccl3 and Cxcl5 (right) in Cre-con and S1pr3-cKO-con groups (n = 2). (B) Heatmap analysis of cell junction related genes (left) and the FPKM of Cdh9 and Cldn5 (right) in Cre-con and S1pr3-cKO-con groups (n = 2). (C) Heatmap analysis of ECM related genes (top) and the FPKM of Fn1 and Snai1 (bottom) in Cre-con and S1pr3-cKO-con groups (n = 2). (D) Heatmap analysis of collagen synthesis related genes (top) and the FPKM of Col6a1 and Col13a1 (bottom) in Cre-BLM and S1pr3-cKO-BLM groups (n = 2). (E) The mRNA expression of Cdh2, Acta2, Fn1 and Cdh1 in Cre-BLM and S1pr3-cKO-BLM groups by RT-qPCR (n = 3). (F) Western blot and quantitative statistics of ZO-1, E-Cadherin, N-Cadherin, Occludin, Snail and β-Actin in the lung tissues of Cre-con and S1pr3-cKO-con groups (n = 4). (G) Western blot and quantitative statistics of ZO-1, Occludin, Claudin-4, Snail, Slug and β-Actin in the lung tissues of Cre-BLM and S1pr3-cKO-BLM groups (n = 4). (H) Representative images of IF staining and MFI of Occludin immunofluorescence in the lung tissues of Cre-BLM and S1pr3-cKO-BLM groups. Bars represent mean ± SEM, ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 S1PR3 inhibition by siRNA and TY52156 could enhance barrier integrity by increasing the expression of cell junction protein To investigate whether epithelial S1PR3 inhibition affects barrier integrity in vitro, S1PR3 was knocked down in human alveolar basal epithelial A549 cells using siRNA (Fig. 6A). The expression of S1PR3 was substantially lower and the expression of the tight junction protein Occludin was notably higher in siRNA-treated cells than in control cells. In addition, the expression of ZO-1 and Claudin-4 was moderately elevated (Fig. 6B-C). Consistently, IF staining showed that S1PR3 knockdown preserved E-cadherin localization resulting in enhancement of adherens junction. (Fig. 6D-E). These findings suggested that epithelial S1PR3 inhibition could increase the expression of tight and adherens junction and improve barrier integrity. Given that epithelial S1pr3 depletion alleviates the progression of PF in S1pr3-cKO mice, we next explored the effect of the S1PR3 antagonist TY52156 in vitro. LPS and BLM, both known to disrupt the epithelial barrier [24], were used to simulate lung epithelial injury and PF in A549 cells. As shown in Fig. 7A, A549 cells were first treated with LPS (5 µg/mL) for 8 h, followed by treatment with TY52156 (10 µM) for 24 h. As shown by Western blot and quantitative analyses (Fig. 7B-C), LPS stimulation markedly downregulated 50% Occludin and Claudin-4 expression, whereas TY52156 considerably restored Occludin expression and modestly 20% increased ZO-1 and Claudin-4 expression. Similarly, IF staining showed that LPS induced prominent stress fiber formation, while TY52156 treatment maintained cortical F-actin organization, resembling the control cells (Fig. 7D-E). Furthermore, transepithelial electrical resistance (TEER) measurements indicated that LPS stimulation reduced resistance, indicating epithelial barrier disruption; in contrast, TY52156 treatment markedly increased resistance by approximately 20% and effectively alleviated LPS-induced epithelial barrier damage in A549 cells (Fig. 7F-G). These results demonstrated that S1PR3 inhibition effectively alleviated barrier impairment triggered by multiple factors under in vitro conditions. In addition, similar method for BLM-induced epithelial cell injury is described in Fig. S6A. A549 cells were first treated with TY52156 (10 µM) overnight, followed by treatment with BLM (40 µM) for 24 h. The Western blot results (Fig. S6B-C) revealed that ZO-1 and Occludin expression was markedly downregulated after BLM challenge, whereas TY52156 treatment restored ZO-1 and Occludin expression levels by approximately 30%. To further evaluate the therapeutic potential of TY52156 in vivo, a BLM-induced PF mouse model was established (Fig. 7H, S6D). TY52156 was administered at two doses: a low dose (3 mg/kg) and a high dose (10 mg/kg), with nintedanib (50 mg/kg) used as a positive control. As expected, TY52156 significantly improved the survival rate by approximately 30% and prolonged the survival time of PF model mice. Notably, the efficacy of high-dose TY52156 (10 mg/kg) was comparable to that of nintedanib. Taken together, these findings demonstrate that S1PR3 inhibition promotes epithelial barrier integrity and improves survival outcomes in PF, suggesting that targeting S1PR3 could be a promising therapeutic strategy for barrier injury-related diseases. Fig. 6S1pr3 inhibition by siRNA could enhance barrier integrity through increasing cell junction related proteins.(A) Experimental design of S1PR3 knockdown in A549 cells by siRNA. (B) Western blot analysis of S1PR3, ZO-1, Occludin, Claudin-4, and β-Actin of control and si-S1PR3 in the A549 cells. (C) Statistical analysis of the expression of the S1PR3, ZO-1, Occludin, Claudin-4 (n = 3). (D) Images of IF staining of E-cadherin in control and si-S1PR3-treated A549 cells (n = 3). (E) MFI of E-cadherin immunofluorescence in control and si-S1PR3-treated A549 cells (n = 3). Bars represent mean ± SEM, ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, ∗∗∗∗P < 0.0001 S1pr3 inhibition by siRNA could enhance barrier integrity through increasing cell junction related proteins.(A) Experimental design of S1PR3 knockdown in A549 cells by siRNA. (B) Western blot analysis of S1PR3, ZO-1, Occludin, Claudin-4, and β-Actin of control and si-S1PR3 in the A549 cells. (C) Statistical analysis of the expression of the S1PR3, ZO-1, Occludin, Claudin-4 (n = 3). (D) Images of IF staining of E-cadherin in control and si-S1PR3-treated A549 cells (n = 3). (E) MFI of E-cadherin immunofluorescence in control and si-S1PR3-treated A549 cells (n = 3). Bars represent mean ± SEM, ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, ∗∗∗∗P < 0.0001 Fig. 7S1pr3 inhibition by TY52156 after LPS-treated could also enhance barrier integrity by increasing the expression of cell junction related proteins. (A) Experimental design of A549 cells treated by LPS and TY52156. (B) Western blot analysis of ZO-1, Occludin, Claudin-4 and β-Actin in A549 cells of control, LPS and TY52156 groups (n = 3). (C) Statistical analysis of the expression of the ZO-1, Occludin, Claudin-4 and β-Actin in A549 cells of control, LPS and TY52156 groups (n = 3). (D) Images of F-actin staining in control, LPS and LPS + TY52156-treated A549 cells (n = 3). (E) MFI of F-actin immunofluorescence in control, LPS and LPS + TY52156-treated A549 cells (n = 3). Bars represent mean ± SEM, ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, ∗∗∗∗P < 0.0001. (F) TEER experiments were conducted by the Millicell voltammeter. (G) TEER (Ω·cm2) = Resistance (Ω) × 0.333 (R = 3.25 mm, S = 0.333 cm2) and standardized by control groups. (H) Survival curves for different treatment groups: Control, Model, Nintedanib (50 mg/kg), low-dose TY52156 (3 mg/kg), and high-dose TY52156 (10 mg/kg) (n = 10–12). Bars represent mean ± SEM, ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 vs. Model group; #P < 0.05, ##P < 0.01 vs. Control group S1pr3 inhibition by TY52156 after LPS-treated could also enhance barrier integrity by increasing the expression of cell junction related proteins. (A) Experimental design of A549 cells treated by LPS and TY52156. (B) Western blot analysis of ZO-1, Occludin, Claudin-4 and β-Actin in A549 cells of control, LPS and TY52156 groups (n = 3). (C) Statistical analysis of the expression of the ZO-1, Occludin, Claudin-4 and β-Actin in A549 cells of control, LPS and TY52156 groups (n = 3). (D) Images of F-actin staining in control, LPS and LPS + TY52156-treated A549 cells (n = 3). (E) MFI of F-actin immunofluorescence in control, LPS and LPS + TY52156-treated A549 cells (n = 3). Bars represent mean ± SEM, ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, ∗∗∗∗P < 0.0001. (F) TEER experiments were conducted by the Millicell voltammeter. (G) TEER (Ω·cm2) = Resistance (Ω) × 0.333 (R = 3.25 mm, S = 0.333 cm2) and standardized by control groups. (H) Survival curves for different treatment groups: Control, Model, Nintedanib (50 mg/kg), low-dose TY52156 (3 mg/kg), and high-dose TY52156 (10 mg/kg) (n = 10–12). Bars represent mean ± SEM, ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 vs. Model group; #P < 0.05, ##P < 0.01 vs. Control group Discussion In this study, to explore the association between S1PR3 and the integrity of the pulmonary barrier, we investigated the regulatory role of epithelial S1PR3 in alveolar‒capillary barrier function. By generating pulmonary epithelial S1pr3-specific knockout mice (S1pr3-cKO) using the CRISPR-Cas9 system, we found that epithelial-specific S1pr3 knockout could alleviate PF by reducing inflammation and collagen deposition, enhancing tight junctions between epithelial cells, and protecting the alveolar‒capillary barrier. PF is a chronic disease with an incompletely understood pathogenesis, and currently, there are no effective therapeutic medications available. Disruption of the alveolar‒capillary barrier, including both endothelial and epithelial injury, contributes to the development of pulmonary diseases [25, 26]. In particular, repetitive epithelial damage is considered a crucial factor in the initiation and progression of PF. Previous studies have indicated that epithelial barrier dysfunction, characterized by epithelial damage, impaired autophagy, and increased permeability, plays a pivotal role in disease development [27–30]. Strieter et al. reported that tumor necrosis factor alpha and interleukin beta (TNF-α and IL-β, respectively) could disrupt the structural integrity and function of the pulmonary epithelial barrier, thereby accelerating PF progression [31–33]. Clinical observations have further shown that IPF patients exhibit increased alveolar permeability and a greater number of apoptotic alveolar epithelial cells [34]. Additionally, in the alveolar epithelial cells of IPF patients in remission, the expression levels of tight junction and adherens junction proteins, such as Claudin-1, Claudin-2, Claudin-3, and Claudin-7, are elevated, which may contribute to lung injury repair and potentially slow the fibrosis process [35]. These findings suggest that a reduction in AT2 cells and the increased expression of tight junction components lead to epithelial barrier disruption and further exacerbate PF. Therefore, elucidating the underlying mechanism of epithelial injury and protecting barrier integrity may offer promising therapeutic strategies for PF. S1P is a bioactive molecule that plays a crucial role in regulating immune responses, angiogenesis, cell migration, and various other physiological and pathological processes through its interaction with five distinct receptors, S1PR1-5. The alveolar‒capillary barrier mainly expresses S1PR1 and S1PR3. Among them, S1PR1 is expressed predominantly in endothelial cells, whereas S1PR3 is expressed at higher levels in alveolar epithelial cells. Previous studies have clarified the regulatory role of endothelial S1PR1 in PF, demonstrating its function in maintaining barrier integrity by enhancing cell junctions and thereby exerting a protective effect against PF [11]; however, the role of S1PR3, which is predominantly expressed in epithelial cells, in regulating the integrity and function of the alveolar‒capillary barrier remains largely unclear. S1PR3 is vital for many physiological and pathological processes, including the regulation of inflammation [36, 37], heart rate [38], cytoskeletal rearrangement [39–41], tumor invasion and metastasis [42], and tissue fibrosis [18, 43, 44]. Murakami et al. [20] reported that S1pr3 knockout alleviates lung fibrosis by inhibiting the expression of connective tissue growth factor (CTGF), a key profibrogenic factor. In addition, Gong et al. reported that miR-495‐3p suppresses the S1PR3 protein by directly binding to its 3′-UTR, thereby inhibiting the epithelial–mesenchymal transition (EMT) process in radiation‐induced PF [45]. Although a study by Murakami and colleagues revealed that S1PR3 knockout can alleviate lung inflammation and reduce collagen deposition in BLM-induced mouse models of PF, these effects are attributed mainly to the role of S1PR3 in regulating the trafficking and activity of inflammatory cells. However, given that S1PR3 expression is markedly upregulated in epithelial cells—especially in injured or fibrotic epithelium—we hypothesized that S1PR3 may directly affect epithelial cell function and thereby influence the fibrotic process. Therefore, for the first time, we generated pulmonary epithelial-specific S1pr3 knockout mice (S1pr3f/f-Sftpc-CreERT2 mice). As SFTPC is a well-established marker for alveolar type II cells, we constructed Sftpc-Cre mice, which, upon tamoxifen administration, enabled lung epithelium-specific deletion of S1pr3, unlike the global S1pr3 knockout mice established by Murakami [20]. Despite the different knockout strategies used, our findings are consistent with those of Murakami et al., reinforcing the notion that S1PR3 is a critical proinflammatory and profibrotic factor involved in the progression of PF. S1pr3 deletion significantly protected survival and lung function following BLM treatment. Histopathological analysis and hydroxyproline quantification further demonstrated that S1pr3 knockout markedly reduced inflammatory cell infiltration, structural damage, and collagen deposition in lung tissue. These findings indicate that S1pr3 knockout in pulmonary epithelial cells could alleviate the progression of BLM-induced PF in mice. The aforementioned results raise the following question: how does lung epithelial S1PR3 regulate the progression of PF? To address this question, we performed RNA-seq to identify gene expression changes following epithelial-specific S1pr3 knockout. RNA-seq analysis revealed that differential expressed genes in the S1pr3-cKO and Cre groups were predominantly enriched in ECM‒receptor interaction pathways. In addition, collagen deposition significantly decreased in the S1pr3-cKO-BLM group after BLM treatment, a result that is consistent with the phenotypes mentioned earlier and might be attributed to enhanced interactions between injured epithelial cells and fibroblasts following BLM-induced damage, leading to fibroblast activation. Disruption of the alveolar‒capillary barrier could facilitate inflammatory cell infiltration. Accordingly, S1PR3 knockout in epithelial cells may influence cellular crosstalk in the fibrotic niche. For example, we observed that the expression of chemokines such as CCL3, CCL5, CCL8, and CXCL5 was reduced following epithelial S1PR3 deletion. However, further experiments are needed to confirm those findings. Moreover, S1pr3 knockout in pulmonary epithelial cells markedly affected the expression of genes associated with adherens and tight junctions. qPCR, Western blot, and immunofluorescence experiments demonstrated that S1pr3 deficiency in pulmonary epithelial cells markedly upregulated the expression of proteins associated with tight junctions (Occludin and Claudin-1) and adhesion junctions (E-cadherin). Our findings were consistent with those reported by Yasuhiro et al., in which S1PR3-null mice exhibited a decrease in Evans blue leakage, suggesting enhanced lung epithelial barrier function. Peng et al. also demonstrated that S1PR3 inhibition could reverse LPS-induced lung endothelial injury and restore adhesion junction protein expression, thereby decreasing the permeability of the pulmonary vasculature [46]. As EMT plays a key role in PF pathogenesis, the expression of Snail and Slug, two key EMT-inducing transcription factors that suppress epithelial marker (e.g., E-cadherin) expression and promote mesenchymal marker (e.g., N-cadherin) expression, were analyzed in our study [47–49]. Snail and Slug expression was significantly lower in the S1pr3-cKO-BLM group than in the Cre-BLM group. Collectively, these findings suggest that epithelial S1pr3 deficiency may alleviate PF by regulating EMT and reinforcing epithelial barrier integrity. Fibrosis, especially PF, which is characterized by epithelial damage and abnormal fibroblast activation, is becoming more common [26], but treatment options remain very limited. TY52156, a dual antagonist of S1PR3 and S1PR4, has been reported to suppress S1P-induced [Ca2+]i elevation and Rho activation and has demonstrated efficacy in treating S1P-related vascular disorders, such as vasospasm [50]. As there are currently no clinically approved inhibitors targeting S1PR3, we employed TY52156—a compound specific for S1PR3—to preliminarily explore the effects of S1PR3 inhibition on PF. In vivo studies have demonstrated that TY52156 confers protective effects in both BLM-induced PF and LPS-induced ALI mouse models by selectively inhibiting S1PR3 [13, 51]. In this study, we employed both TY52156 and S1pr3 siRNA to investigate the effect of S1PR3 inhibition on epithelial barrier integrity in vitro in A549 cells. According to our results, the expression level of Occludin was elevated following S1PR3 inhibition by either siRNA or TY52156, which indicated that S1PR3 suppression could promote barrier integrity in vitro. Our findings further suggest that S1PR3 regulates epithelial barrier integrity partly through modulating the actin cytoskeleton. Inhibition of S1PR3 maintained E-cadherin localization at cell junctions. In contrast, LPS stimulation induced reorganization of cortical F-actin and disrupted cell junctions, indicating increased cytoskeletal tension and compromised barrier integrity. Given the critical role of F-actin dynamics in the assembly and maintenance of tight and adherens junctions, these findings suggest that S1PR3 may regulate epithelial permeability by modulating actin polymerization and junctional tension. To evaluate the effect of S1PR3 inhibition in vivo, we utilized a BLM-induced PF mouse model, which is commonly used to simulate PF [52–54]. TY52156 treatment improved the survival of PF mice, comparable to nintedanib. It also ameliorated pulmonary function parameters including Crs, Ers, and Rrs, though no significant change was observed in IC (Fig. S6). Although previous studies have shown that TY52156 can attenuate inflammatory responses [13, 55], its potential role in modulating fibrosis progression has not been fully elucidated. A plausible explanation for this discrepancy lies in the broad expression of S1PR3 across various cell types in the lung [56]. As such, TY52156 might affect not only epithelial cells but also other cell types, such as endothelial and immune cells, potentially affecting vascular permeability and other aspects of lung pathology. To address this, our future investigations will seek to validate the effects of TY52156 on nonepithelial cells, including inflammatory and endothelial cells. Additionally, TEER measurements were conducted using A549 cells rather than primary alveolar epithelial cells. Owing to technical constraints, it was challenging to obtain sufficient primary cells, which also tend to lose polarity and form incomplete tight junctions during in vitro culture. Therefore, A549 cells were employed as a practical model; however, future studies should confirm these findings in primary alveolar epithelial cells. Further investigations are needed in the future to elucidate the precise mechanism by which S1P3 disrupts the epithelial barrier via cytoskeletal reorganization in lung epithelial cells. Limited by the number and batch of animals, we pooled lung epithelial cells from two mice per sample for RNA sequencing of primary cells from S1pr3-cKO mice. To further ensure the reliability of our conclusions, we complemented this approach with in vitro cell experiments and in vivo validation using the BLM-induced pulmonary fibrosis model to assess the effects of S1PR3 inhibition. Moreover, considering that S1PR3 is also expressed in fibroblasts, endothelial cells, and immune cells, its role in intercellular communication and its contribution to inflammatory and fibrotic processes in PF warrant further investigation. Advanced techniques such as single-cell RNA sequencing and the development of highly selective S1PR3 modulators may provide deeper insights into the multifaceted role of S1PR3 in PF pathogenesis. Conclusion In conclusion, our study revealed that epithelial-specific S1pr3 knockout could alleviate PF by promoting epithelial cell junctions and protecting the alveolar‒capillary barrier. The inhibition of S1PR3 by small-molecule inhibitors and siRNAs alleviated epithelial barrier injury. Therefore, targeting S1PR3 may represent a promising therapeutic strategy for PF by enhancing alveolar epithelial barrier function. Supplementary Information Supplementary Material 1 Supplementary Material 1 Supplementary Material 2 Supplementary Material 2